Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study-Reference-Cited by-同舟云学术

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study

Published:2021-04 Issue:1 Volume:161 Page:113-121
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Leslie Kimberly K.,Filiaci Virginia L.,Mallen Adrianne R.,Thiel Kristina W.,Devor Eric J.,Moxley Katherine,Richardson Debra,Mutch David,Secord Angeles Alvarez,Tewari Krishnansu S.,McDonald Megan E.,Mathews Cara,Cosgrove Casey,Dewdney Summer,Casablanca Yovanni,Jackson Amanda,Rose Peter G.,Zhou XunClare,McHale Michael,Lankes Heather,Levine Douglas A.,Aghajanian Carol

Funder

Stand Up To Cancer

National Cancer Institute

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference36 articles.

1. Effects of bevacizumab in mouse model of endometrial cancer: defining the molecular basis for resistance;Davies;Oncol. Rep.,2011

2. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer;Kamat;Clin. Cancer Res.,2007

3. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study;Aghajanian;J. Clin. Oncol.,2011

4. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer;Aghajanian;Gynecol. Oncol.,2018

5. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 – a randomized phase II trial;Lorusso;Gynecol. Oncol.,2019

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer;Gynecologic Oncology;2024-08

2. Treatment options in the advanced and recurrent setting for endometrial cancer: an update;Expert Review of Anticancer Therapy;2024-06-24

3. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study;Gynecologic Oncology;2024-06

4. Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection;International Journal of Molecular Sciences;2024-05-28

5. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer;Cancer Treatment Reviews;2024-05